On May 10, 2001, McCauley, John A.; Theberge, Cory R.; Liverton, Nigel J.; Claremon, David A.; Claiborne, Christopher F. published a patent.Formula: C7H5FN2 The title of the patent was Preparation of 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists. And the patent contained the following:
Novel benzimidazoles, substituted in the 2-position by substituted benzyl groups or heteroaryl groups, (I) [wherein R1, R2, R4, and R5 = independently H, Cl, F, OH, OMe, CF3, OCF3, NH2, CN, NO2, (amino)alkyl, aryl, alkylcarbonylamino, oxohydroxydibenzopyranyl-substituted carboxyphenylthioureido or carbonylaminoalkylcarbonylamino, R6SO2NH, R6SO2NMe, or R6SO2NHCH2; R3 = H, OH, NH2, alkylamino, arylamino, or :O; R6 = (un)substituted alkyl, (phenyl)alkenyl, Ph, naphthyl, or heterocyclic group; Y = O, NH, (CH2)nCO(CH2)n, or (CH2)nCHR3(CH2)n; n = 0-5; Ar may be substituted with 0-3 N atoms in positions 2, 3, 5, or 6] were prepared as effective NMDA NR2B glutamate receptor antagonists. For example, cycloaddition of phenylenediamine and (4-phenoxyphenyl)acetic acid in presence of EDC and HOBt in DMF afforded 2-(4-phenoxybenzyl)-1H-benzimidazole. Exptl. protocols for assessing the inhibition of NR1A/2B NMDA receptor activation (FLIPR assay) and determining the apparent dissociation constants against the human NR1A/NR2B receptor (binding assay) are given (no data). I are useful for relieving pain and treating depression, schizophrenia, Parkinson’s disease, or stroke (no data). The experimental process involved the reaction of 2-(6-Fluoropyridin-3-yl)acetonitrile(cas: 337965-61-4).Formula: C7H5FN2
The Article related to benzimidazole preparation analgesic, benzyl benzimidazole preparation glutamate receptor antagonist, heteroaryl benzimidazole preparation nmda nr2b antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Formula: C7H5FN2
Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts